Skip to main content
Premium Trial:

Request an Annual Quote

Ruth VanBogelen, Walid Qoronfleh, David Holbrook

Premium
NextGen Sciences has appointed Ruth VanBogelen and Walid Qoronfleh to executive positions in its protein biomarker team as part of a strategy to focus on biomarker services. The company has named VanBogelento the role of director of biomarkers and proteomics, and Qoronfleh to be VP of business development.
 
VanBogelen comes to NextGen from Pfizer, where she also served as director of proteomics R&D, and she has thirty years of experience in proteomics, including leading microbial proteomics studies at the University of Michigan Medical Center.
 
Qoronfleh previously was founder and managing director of Q3 Consulting Group, and he spent twenty years holding various executive positions at AntexPharma, Pierce Biotechnology, and at CTA Corp/University of Michigan-Ann Arbor. He also held scientific and R&D appointments at SmithKline Beecham, Sterling Winthrop Pharmaceuticals, and at the National Cancer Institute.
 

 
The UK molecular diagnostics company Myconostica has tapped David Holbrook, manager of the UMIP Premier Fund, to join the company’s board of directors.
 
Holbrook has worked in hospital medicine and in business development and licensing in the pharmaceutical industry.
 
Last week, the UMIP Premier Fund invested £1 million ($1.98 million) to close out a £5.4 million round of Series C financing for Myconostica.

Filed under